PSA Recurrence After Radical Prostatectomy
For patients with a PSA biochemical recurrence after prostate removal through surgery
Treatment Options
No Distant Metastases
Life expectancy more than 5 years; studies negative for distant metastases and pelvic recurrence
EBRT or
EBRT + ADT or
Monitoring: History and physical exam every 12 months or as needed
Life expectancy more than 5 years; pelvic recurrence biopsy positive
EBRT + ADT
EBRT + ADT + abiraterone (Zytiga)
EBRT + ADT + abiraterone (Yonsa)
With Distant Metastases
- EBRT + Androgen Deprivation Therapy (ADT)
- EBRT + ADT +
– Abiraterone (Zytiga), or
– Abiraterone (Yonsa)
Life Expectancy: 5 years or Less
- Observation: History and physical exam every 12 months or as needed
CLINICAL TRIALS:
NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer Version 4.2023
© National Comprehensive Cancer Network, Inc. 2022. All rights reserved. The complete and current version of the guideline is available at NCCN.org.
IMPORTANT:
This information is provided for educational purposes only to support patients in understanding and discussing appropriate treatment options with their doctors. Included is information from treatment guidelines for doctors and other sources. However, this information should not be considered as patient treatment guidelines or recommendations, but as educational materials only. Patients should discuss treatments identified herein with their doctors to understand the risks and benefits of each based on their personal diagnosis. Treatment decisions should only be made between the patient and his doctor.
